Q2 2025 Lupin Ltd Earnings Call Transcript
Key Points
- Lupin Ltd (BOM:500257) reported double-digit revenue growth, driven by strong commercial execution and new product launches.
- The company achieved a 510 basis points improvement in EBITDA year-over-year, with margins expected to remain in the 22% to 23% range.
- Strong performance in the US market, particularly in the respiratory portfolio, with successful launches like mirabegron 50-milligram.
- India business grew 19% year-over-year, outperforming the market with significant growth in key therapy areas such as diabetes.
- Non-US developed markets saw a 20% year-over-year growth, with strong contributions from Canada, UK, and Australia.
- Increased competition in the US market for products like Suprep and doxycycline impacted sales.
- Higher R&D expenses, which increased to 8.2% of sales, could pressure margins if not offset by revenue growth.
- Employee benefit expenses rose by 17% year-over-year, impacting overall profitability.
- The company faces ongoing FDA compliance challenges, with recent audits at Pune Biotech and Pithampur Unit 1 facilities.
- The tender business, while profitable, is inherently sporadic, leading to potential revenue volatility.
Welcome to Lupin Limited Q2 FY25 earnings conference call. Please note that all participants line will be in listen-only mode and there will be an opportunity for you to ask questions after the opening remarks. Please note that this conference is being recorded. I now hand the conference over to the management. Thank you and over to you.
Good evening, everyone. I hope all of you had a great Diwali. I'm very pleased to welcome you to our Q2 fiscal year '25 earnings call. I have with me our MD, Nilesh; our CFO, Ramesh; and our Head of Investor Relations, Ravi here. We look forward to sharing with you our highlights for the quarter as well as outlook for the year ahead.
We are very happy to report another quarter of double-digit revenue growth, led by strong commercial execution in our key markets and also backed by new product launches. We are particularly pleased with our EBITDA performance with 510 basis points improvement year-over-year and 50 basis points improvement sequentially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
